Cargando…

Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a member of the large ErbB family and an important oncogene in many solid tumors. Pyrotinib has been approved for the treatment of HER2-positive, recurrent, or metastatic breast cancer. However, there are very few clinical studies on pyr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jianzheng, Zhang, Baiwen, Cheng, Xiaojiao, Li, Qingli, Lv, Huifang, Nie, Caiyun, Chen, Beibei, Xu, Weifeng, Zhao, Jing, He, Yunduan, Tu, Shuiping, Chen, Xiaobing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975634/ https://www.ncbi.nlm.nih.gov/pubmed/35368895 http://dx.doi.org/10.1155/2022/4233782

Ejemplares similares

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
por: Wang, Jianzheng, et al.
Publicado: (2021)

Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review
por: Wang, Jianzheng, et al.
Publicado: (2022)

Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma
por: Xu, Weifeng, et al.
Publicado: (2022)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study
por: Nie, Caiyun, et al.
Publicado: (2023)

The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study
por: Nie, Caiyun, et al.
Publicado: (2021)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
por: Lv, Huifang, et al.
Publicado: (2023)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
por: Chen, Beibei, et al.
Publicado: (2022)

Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model
por: Wang, Jianzheng, et al.
Publicado: (2022)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
por: Li, Qingli, et al.
Publicado: (2022)

Dawning precision treatment for gastric cancer: The latest biomarkers
por: Sun, Keran, et al.
Publicado: (2021)

Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer
por: Lv, Huifang, et al.
Publicado: (2021)

Corrigendum: Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer
por: Lv, Huifang, et al.
Publicado: (2021)

Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors
por: Huang, Tinglei, et al.
Publicado: (2021)

Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway
por: Li, Fuli, et al.
Publicado: (2021)

Overview on the Role of E-Cadherin in Gastric Cancer: Dysregulation and Clinical Implications
por: Zhao, Huichen, et al.
Publicado: (2021)

Bone Marrow-Derived Myofibroblasts Promote Gastric Cancer Metastasis by Activating TGF-β1 and IL-6/STAT3 Signalling Loop
por: Wang, Jianzheng, et al.
Publicado: (2020)

Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer
por: Yin, Yuzhen, et al.
Publicado: (2020)

Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2(+) breast cancer with brain metastasis: a retrospective cohort study
por: Chen, Jiaxin, et al.
Publicado: (2022)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer
por: Chen, Hao, et al.
Publicado: (2023)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways
por: Su, Beibei, et al.
Publicado: (2020)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases
por: Huang, Jie, et al.
Publicado: (2023)

Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
por: Li, Yan, et al.
Publicado: (2022)

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
por: Song, Zhengbo, et al.
Publicado: (2022)

The efficacy and safety of pyrotinib in treating HER2‐positive breast cancer patients with brain metastasis: A multicenter study
por: Gao, Min, et al.
Publicado: (2021)

Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells
por: Huang, Tingting, et al.
Publicado: (2020)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
por: Zhang, Xinyong, et al.
Publicado: (2020)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2(+) Breast Cancer Cells to 5-Fluorouracil
por: Yi, Jianing, et al.
Publicado: (2020)

MicroRNA-6884-5p Regulates the Proliferation, Invasion, and EMT of Gastric Cancer Cells by Directly Targeting S100A16
por: Lv, Huifang, et al.
Publicado: (2020)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023)

Knockdown of Kremen2 Inhibits Tumor Growth and Migration in Gastric Cancer
por: Chen, Beibei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8b8onja1konge9f4is57mas8bg